Hybrid PET/MRI Assessment with Hippocampal Radiomics May Facilitate Early Alzheimer's Diagnosis


Employing a hybrid positron emission tomography (PET)/magnetic resonance imaging (MRI) model to assess predictive features of Alzheimer’s disease (AD), researchers noted a 100 percent sensitivity rate and a 93 percent sensitivity rate for distinguishing between AD and normal cognition, according to a study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.

Assessing predictive hippocampal radiomic features with a multimodal combination of positron emission tomography (PET) and magnetic resonance imaging (MRI) may lead to earlier detection of Alzheimer’s disease (AD), according to new research presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.

Noting key early predictive features for AD, ranging from glucose metabolism to decreased cerebral blood flow and hippocampal atrophy, researchers assessed a multiparametric imaging model for differentiating between AD, mild cognitive impairment (MCI) and normal cognition (NC) in 159 patients.1 The imaging model included the use of arterial spin-labeling (ASL) T1-weighted MRI and 18F-fluorodeoxyglucose PET (18F-FDG PET), according to the study.

With the fivefold cross-validation logistic regression model, the researchers found an area under the curve (AUC) of 98 percent as well as a 93 percent specificity rate and a 100 percent sensitivity rate for differentiating between AD and NC.1

For the differentiation of AD and MCI, the study authors noted an AUC of 85 percent, 88 percent sensitivity and 73 percent specificity. The multiparametric imaging model also demonstrated an AUC of 86 percent, 80 percent sensitivity and 81 percent specificity for differentiating between MCI and NC, according to the study.1

“Our findings demonstrate that multi-dimensional imaging of the hippocampal radiomics benefits the identification of early AD and may provide a potential biomarker for clinical applications in AD,” noted Jie Lu, M.D., who is affiliated with the Department of Radiology and Nuclear Medicine at Xuanwu Hospital and Capital Medical University in Beijing, China, and colleagues.

(Editor’s note: For related content, see “GE HealthCare Debuts New PET/MRI System at SNMMI Conference,” “FDA Clears AI-Powered MRI Software to Assess for Brain Atrophy” and “Brain PET Study Suggests Link Between Early Amyloid Accumulation and Repetitive Subconcussive Trauma.”)


1. Chen Z, Yan S, Bi S, Cui B, Yang H, Lu J. Early diagnosis of Alzheimer’s disease using multiparametric hippocampal signatures with 18F-FDG PET/MR radiomics. Poster presented at Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting June 24-June 27, Chicago. Available at: https://am.snmmi.org/imis/SNMMI-AM . Accessed June 29, 2023.

Related Videos
Emerging Innovations in Molecular Imaging
Ultra-High Resolution Brain PET: A ‘Quantum Leap’ for Neuroradiology
Emerging PET Radiotracer May Improve Detection of Coronary Artery Disease in Obese Patients
Can SPECT/CT Guidance Facilitate Personalized Dosing for Patients with Prostate Cancer?
New Research Shows Viability of PET Imaging Agent for Clear Cell Renal Cell Carcinoma
A Closer Look at Urinary Activity and PET Radiopharmaceuticals for Prostate Cancer Imaging
Expediting the Management of Incidental Pulmonary Emboli on CT
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
Related Content
© 2023 MJH Life Sciences

All rights reserved.